Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2022

View Archived Issues

YAP1/TAZ signaling plays a role in colorectal cancer

CAR plus a CD38-directed chimeric costimulatory receptor enhances tumor killing

Suzhou Vintagence Pharma discloses new GTPase KRAS mutant inhibitors

Chinese researchers patent new antibacterial compounds

Wuhan LL Science and Technology Development divulges TRPC5 antagonists

Medshine Discovery synthesizes new ER-alpha degradation inducers

Shanghai Newsky Biotechnology identifies PLA2G7 inhibitors

CBD inhibits SARS-CoV-2 replication during early stages of infection in mice

Qualigen to develop G4-selective transcription inhibitor from UCL for cancer

PL-8177 shows promise in preclinical models of induced colitis

KIN-3248 shows efficacy against tumors with clinically relevant FGFR mutations

ImmVira leverages viral vectors to enable CAR-T therapy for solid tumors

AB1 protein targets TP53-mutated gastrointestinal tumors

Anixa and MolGenie report in vitro data on SARS-CoV-2 protease inhibitor

Molecular mimicry triggers multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...